NASDAQ$PIII
P3 Health Partners Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
P3 Health Partners' third quarter performance was affected by lower risk adjustments, higher medical expenses, and retroactive adjustments.
P3 Health Partners reported a 26% year-over-year increase in revenue to $362.1 million. However, the quarter was impacted by lower risk adjustments, higher medical expenses, and retroactive adjustments, leading to a net loss of $102.9 million and the withdrawal of the company's previous fiscal year guidance.
- Total revenue increased by 26% year-over-year, reaching $362.1 million.
- Capitated revenue grew by 25% year-over-year, totaling $357.7 million.
- Gross profit was a loss of $39.8 million, compared to a gross profit of $9.1 million in the prior year.
- Net loss was $102.9 million, compared to a net loss of $37.3 million in the prior year.
Headline financials
Revenue & EPS history
P3 Health · Revenue · Quarterly
$362M
Revenue by segment
P3 Health · $386M total across 2 segments · Q1 2026
- Capitated Revenue$379M—98.2%
- Other Revenue$6.89M—1.8%
Forward guidance
In light of a lower-than-expected 2024 risk adjustment, negative prior year developments, and continued elevated medical cost pressures, the Company is withdrawing its previous guidance for fiscal year ending December 31, 2024, provided on its second quarter 2024 earnings call on August 7, 2024, and investors should no longer rely on it.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2024
-3.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
-2.0%
Avg return
30 days after
37%
7 / 19 earnings
Positive
+11.2%
Q1 2026
Best reaction
-36.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.7% | -9.7% | — | |
| Q1 2026 | +11.2% | +194.4% | +239.9% | |
| Q3 2025 | +0.4% | -12.6% | -25.9% | |
| Q2 2025 | -2.5% | +5.4% | +23.9% | |
| Q1 2025 | -0.6% | -5.9% | -19.5% | |
| Q4 2024 | -4.5% | +1.1% | -1.2% | |
| Q3 2024 | -36.8% | -42.2% | -46.0% | |
| Q2 2024 | -2.5% | -8.7% | -24.1% | |
| Q1 2024 | +2.6% | -11.8% | -21.6% | |
| Q4 2023 | -13.3% | -22.4% | -56.3% | |
| Q4 2021 | +3.1% | -7.6% | -12.2% | |
| Q3 2023 | -2.1% | -8.8% | -19.0% | |
| Q2 2023 | +0.9% | -10.8% | -5.0% | |
| Q4 2022 | -5.9% | -12.7% | +15.5% | |
| Q3 2022 | -11.8% | -19.7% | -33.5% | |
| Q1 2022 | -5.9% | +2.1% | -16.8% | |
| Q2 2022 | -4.1% | +0.6% | -14.0% | |
| Q3 2021 | +0.1% | +0.3% | -19.9% | |
| Q2 2021 | -0.7% | -0.2% | +0.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro